NCT04711226View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

February 19, 2021

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2026

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

AT-1501

AT-1501 IV infusion

Trial Locations (1)

T6G 2E1

University of Alberta, Edmonton

Sponsors
All Listed Sponsors
lead

Anelixis Therapeutics, LLC

INDUSTRY

NCT04711226 - Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation | Biotech Hunter | Biotech Hunter